EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of EphA2 positive cancer comprising cancer cells expressing over about 3000 EphA2 receptors/cell. Diagnostic methods for identifying EphA2 positive cancer patients and methods of treating identified patients with a Eph-A2 targeted nanoliposome encapsulating a docetaxel prodrug are provided.

A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of cancer overexpressing EphA2, alone or in combination with chemotherapeutic agents such as gemcitabine or carboplatin.

The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.

Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles.

The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.

A construct, or a pharmaceutically acceptable salt thereof, comprising: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a siRNA complexed with the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.

A pharmaceutical composition, a preparation method thereof, and an application of same. The pharmaceutical composition comprises an active ingredient, a polymer, and a surfactant, wherein the surfactant comprises a bile salt. The pharmaceutical composition is prepared as a nanoparticle.

Provided herein are antibiotic coated nanoparticles and methods of treating bacterial infection therewith. In particular embodiments, polymyxin B, vancomycin, and/or other antibiotics are linked to nanoparticles (e.g., gold or silica nanoparticles) and utilized for the treatment of bacterial infections.

The application relates to liposomal nanovesicles comprising porphyrin-lipid conjugates within the liposomal lipid bilayer. Said porphyrin-lipid conjugate comprise porphyrins that are modified with a -CH(R1)-O-R2 group and that chelate a metal ion. Such modifications of the porphyrin allow for ordered assembly in the lipid bilayer of the nanovesicles while resulting in a bathochromic shift in the wavelength of light absorbed by the porphyrin chromophore. These nanovesicles can be used for photothermal therapy, photodynamic therapy, photoacoustic imaging and fluorescence imaging. The application also teaches methods for preparing the porphyrin-lipid conjugates and the nanovesicles.

The present invention provided an anticancer nano-silver composition for the treatment and prevention of cervical cancer. The composition contains nano-silver powder 3-200 mg/kg, carbomer 700-1000 mg/kg, triethanolamine 700-1000 mg/kg, glucose 2.8-3.2 g/kg, and water as remaining; of the nano-silver powder, wherein the purity of silver is ≧99.99% and particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit HeLa proliferation, and cause cell death. The anticancer nano-silver composition of the present invention can be used to manufacture medicaments for the treatment and prevention of cervical cancer.

Provided are a nanocarrier-drug composite for treating cancer and a manufacturing method thereof, the nanocarrier-drug composite comprising UCNPs functioning as a core, a layer of porous material coated on the surface of the core having an anti-cancer drug loaded in the pores, and a layer of a basic manganese compound deposited on the surface of the porous material. The surface of the basic manganese compound is labeled with one or more capture molecules or recognition molecules.

Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.

In one aspect, a particle comprising a core containing at least one pharmaceutically active agent and a coating covering the surface of the particle that comprises a biocompatible adhesive polymer is provided. The core may comprise two or more components, such as two pharmaceutically active agents or a pharmaceutically active agent and a major constituent of the core, having at least one dissimilar chemical or physical property (e.g., molecular weight, solubility, c Log P). In some such embodiments, placement of the uncoated core in certain environments results in the rapid release of a component (e.g., a pharmaceutically active agent) from and/or destabilization and breakdown of the core. In some embodiments, the biocompatible adhesive polymer in the coating acts as a molecular glue to stabilize the core and/or alter the release kinetics of at least one pharmaceutically active agent.

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Lipidic compound (lipidic molecule)-telodendrimer hybrid nanoparticles. For example, the lipidic compound-telodendrimer hybrid nanoparticles are lipid/lipidoid-telodendrimer hybrid nanoparticles. The nanoparticles can comprise a plurality of lipidic molecules (e.g., lipid molecules, lipidoid molecules, or mixtures of different lipid molecules or different lipidoid molecules). The hybrid nanoparticles can comprise one or more lipid or lipidoid and one or more telodendrimer. The hybrid nanoparticles can also comprise cholesterol. In various examples, the hybrid nanoparticles also comprise a small molecule, peptide, protein, or a combination thereof. In various examples, lipid-telodendrimer hybrid nanoparticles comprising one or more small molecules or lipidoid-telodendrimer hybrid nanoparticles comprising one or more protein(s) and/or peptide(s) are used in methods of small-molecule or protein/peptide delivery.

Chewing gum including a liquid center, a chewy layer surrounding the liquid center, and a coating surrounding the chewy layer. The liquid center includes a nanozome encapsulated dose of a cannabinoid such as cannabidiol of approximately 1-30 mg. The nanozome is preferably a phospholipid such as a Phosphatidyl Choline. In another embodiment the nanozome is unsaturated Phosphatidyl Choline to improve bioavailability of the cannabidiol, or other cannabinoid.

Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.

EphA2-targeted immunoliposomes for delivering docetaxel are useful in the treatment of certain types of cancer. The immunoliposomes can include an EphA2 targeting moiety (e.g., a scFv) and encapsulate a docetaxel prodrug in a stable salt form within a liposome having an average size of about 100 nm. Novel docetaxel prodrugs suitable for loading into nanoliposomes (including immunoliposomes) are provided, along with novel and other useful EphA2 targeting moieties for preparation of EphA2-targeted doxorubicin-generating immunoliposome therapies. Pharmaceutical compositions can be prepared that include nanoliposomes encapsulating one or more docetaxel prodrugs, and/or immunoliposomes or nanoparticles comprising an EphA2 binding moiety and encapsulating one or more docetaxel prodrugs. The pharmaceutical compositions are useful for administration to a patient for the treatment of cancer.

Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

本发明属于药物制剂新辅料和新剂型领域，涉及种肠道上皮细胞顶侧OCTN2转运体的底物L‑肉毒碱的衍生物和相应靶向纳米粒的制备，及其作为口服药物载体在药物传递方面的应用。本发明所述的硬脂酰‑L肉毒碱由OCTN2转运体底物L‑肉毒碱和硬脂酸组成的两亲性化合物，是种稳定性好的用于构建OCTN2靶向纳米药物传递系统的靶向配基。所述的硬脂酸可以为十八酸、十六酸、十四酸等长链脂肪酸。所述的两亲性化合物的结构式如下：

本发明涉及种白蛋白纳米粒的制备方法及通过该方法制备的白蛋白纳米粒以及该白蛋白纳米粒的制药用途。更具体地，本发明涉及种白蛋白纳米粒的制备方法，该方法包括以下步骤：1)将白蛋白溶解于脲溶液中混匀后，加入硼氢化钠溶液，得到变性白蛋白的脲溶液；2)将无水乙醇或其他有机溶剂加入到所述白蛋白变性的脲溶液中，然后加入纯化水，即形成白蛋白纳米粒。此外，本发明还涉及由上述方法制备的白蛋白纳米粒以及该白蛋白纳米粒的制药用途。

Resumen de: CN107158401A

本发明提供了种聚乙二醇修饰的钙基纳米药物递送颗粒及其制备方法和应用。本发明提供的所述聚乙二醇修饰的钙基纳米药物递送颗粒的粒径为20～200nm；所述聚乙二醇修饰的钙基纳米药物递送颗粒包括第目标投递物、包裹有第目标投递物的钙基颗粒，其中，所述钙基颗粒表面修饰有聚乙二醇，所述第目标投递物为生物药物、化学药物或包载有核酸片段的第二目标投递物，所述包载有核酸片段的第二目标投递物为包裹、结合或共混有核酸片段的阳离子聚合物、多肽、聚氨基酸或转染试剂。本发明提供的聚乙二醇修饰的钙基纳米药物递送颗粒不仅在制备过程中纳米颗粒的粒径可控，钙基颗粒表面有聚乙二醇链保护，从而延长体内循环的时间，而且制备成本低、毒性低，安全有效。